- Home
- ENVB vs SNOA Comparison
ENVB vs SNOA Comparison
Compare ENVB & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- SNOA
- Stock Information
- Founded
- ENVB 1994
- SNOA 1999
- Country
- ENVB United States
- SNOA United States
- Employees
- ENVB N/A
- SNOA N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- SNOA Health Care
- Exchange
- ENVB Nasdaq
- SNOA Nasdaq
- Market Cap
- ENVB 4.1M
- SNOA 3.7M
- IPO Year
- ENVB N/A
- SNOA 2007
- Fundamental
- Price
- ENVB $0.35
- SNOA $2.65
- Analyst Decision
- ENVB Strong Buy
- SNOA
- Analyst Count
- ENVB 1
- SNOA 0
- Target Price
- ENVB $10.00
- SNOA N/A
- AVG Volume (30 Days)
- ENVB 1.0M
- SNOA 44.7K
- Earning Date
- ENVB 11-14-2024
- SNOA 02-06-2025
- Dividend Yield
- ENVB N/A
- SNOA N/A
- EPS Growth
- ENVB N/A
- SNOA N/A
- EPS
- ENVB N/A
- SNOA N/A
- Revenue
- ENVB N/A
- SNOA $13,547,000.00
- Revenue This Year
- ENVB N/A
- SNOA $23.89
- Revenue Next Year
- ENVB N/A
- SNOA $25.45
- P/E Ratio
- ENVB N/A
- SNOA N/A
- Revenue Growth
- ENVB N/A
- SNOA 11.81
- 52 Week Low
- ENVB $0.30
- SNOA $2.44
- 52 Week High
- ENVB $2.92
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- ENVB 46.61
- SNOA 47.13
- Support Level
- ENVB $0.35
- SNOA $2.52
- Resistance Level
- ENVB $0.39
- SNOA $2.80
- Average True Range (ATR)
- ENVB 0.05
- SNOA 0.13
- MACD
- ENVB -0.00
- SNOA 0.00
- Stochastic Oscillator
- ENVB 19.56
- SNOA 39.39
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.